Connor, Clark & Lunn Investment Management Ltd.

Position in PTGX — Protagonist Therapeutics, Inc

CIK 1596800 VANCOUVER, A1

Position in PTGX

as of Jun 30, 2026 · filed Aug 13, 2026 Compact

Position Value

$3,574,555

+$701,351 QoQ

Shares Held

29,161

+7.0% QoQ

Ownership

0.045%

of shares outstanding

% of Portfolio

0.01%

of 13F equity value

Holder Rank

#112

of 341 holders

Holding Since

Jun 2020

12 quarters on record

Voting authority Sole 100% Shared 0% None 0%

Healthcare · as of Jun 30, 2026

Connor, Clark & Lunn Investment Management Ltd. holds $650,455,382 across 105 Biotechnology names. PTGX ranks #36 (0.5% of the industry book) .

#	Ticker	Company	Shares	Value (USD)
1	VRTX	Vertex Pharmaceuticals Inc / Ma	135,236	$67,175,777
2	IONS	Ionis Pharmaceuticals Inc	684,236	$54,253,072
3	ARWR	Arrowhead Pharmaceuticals, Inc.	625,569	$50,990,129
4	MIRM	Mirum Pharmaceuticals, Inc.	420,063	$49,176,775
5	REGN	Regeneron Pharmaceuticals, Inc.	42,465	$26,478,625
6	AXSM	Axsome Therapeutics, Inc.	97,698	$23,913,539
7	INSM	INSMED Inc	212,676	$22,675,515
8	VKTX	Viking Therapeutics, Inc.	530,607	$20,698,979

12 filing rows on record

Report Date	Value (USD)	Shares	Change	Type	Discretion	Filed
2026-06-30	$3,574,555	29,161	+7.0%	Shares	Sole	2026-08-13
2026-03-31	$2,873,204	27,260	+105.4%	Shares	Sole	2026-05-11
2025-12-31	$1,159,001	13,270	-84.0%	Shares	Sole	2026-02-10
2024-06-30	$2,868,708	82,791	-11.2%	Shares	Sole	2024-08-09
2024-03-31	$2,695,870	93,186	-13.3%	Shares	Sole	2024-05-09
2023-12-31	$2,465,938	107,542	-22.9%	Shares	Sole	2024-02-09
2023-09-30	$2,326,759	139,494	-14.6%	Shares	Sole	2023-11-13
2023-06-30	$4,513,798	163,425	+33.9%	Shares	Sole	2023-08-10
2023-03-31	$2,806,552	122,024	-37.3%	Shares	Sole	2023-05-10
2022-12-31	$2,124,220	194,704	+1.8%	Shares	Sole	2023-02-10
2022-09-30	$1,611,756	191,193	+568.6%	Shares	Sole	2022-11-10
2020-06-30	$505,040	28,598	—	Shares	Sole	2020-08-13
No filing history on record for this holder in this stock.